MedPage Today (11/2, Grant) reports, “Esketamine nasal spray (Spravato) combined with an oral antidepressant for treatment-resistant depression reduced depression severity and led to numerically more remissions during maintenance, post-hoc analyses of three phase III trials” indicated. The findings were presented at the Psych Congress 2021. The article adds, “As MedPage Today reported at the 2019 American Psychiatric Association annual meeting, three suicides were reported among patients with treatment-resistant depression treated with esketamine during clinical trials – occurring 4, 12, and 20 days after the patients’ last dose – while none were reported from the respective placebo groups.” (SOURCE: APA Headlines)